Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
doi: 10.1016/j.toxrep.2020.08.001
Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with type 2 diabetes and obesity
If confirmed severe gastroparesis is attributed to GLP-1 therapy, medication discontinuation is generally recommended, with most patients experiencing gradual symptom improvement over weeks to months
It is worth noting that a trial of the anti-diabetic agent pioglitazone (PPAR agonist) in ALS with the rationale of attenuating inflammation, failed to show any benefit 9
Emerging competitive pressure is also building from smaller biotechnology firms developing next-generation dual and triple agonist molecules, positioning the market for intensified competition as new mechanisms of action and delivery formats advance through late-stage clinical development in the coming years
Federici, M
